Newsroom
  • Press Releases
  • Presentations
Investors
  • Overview
  • Warrant Exercise Inquiries
  • Restricted Stock Inquiries
  • Notice to Stockholders
  • News / Events
  • Company Information
  • Financial Information
  • Stock Data
  • SEC Filings
  • Corporate Governance
Clinical Trial Enrollment
  • Triple-Negative Breast Cancer
  • COVID-19 Mild to Moderate
  • COVID-19 Severe or Critical
  • COVID-19 Long-Haulers
Contact

CytoDyn Inc.

  • Home
  • About CytoDyn
    • Meet CytoDyn
  • Our Science
  • Pipeline
    • Overview
    • HIV
    • Cancer
    • GVHD
    • COVID-19
  • Expanded Access
  • Our Team
    • Management Team
    • Board of Directors
  • Careers
    • Now Hiring
  • Scientific Board of Advisors
  • Newsroom
  • Investors
  • Clinical Trial Enrollment
  • Contact
Latest News

FOR THE LATEST DEVELOPING NEWS Click Here

Hospitals Enrolling COVID-19 Severe-to-Critical

Investment Community Webcast on Wednesday, April 7

Antibody-based strategies in HIV therapy

Leronlimab in International Journal of Infectious Diseases

Manuscript Accepted by Infectious Diseases Society of America

Into the Looking Glass: Post-Viral Syndrome Post COVID-19

Local drug trial provides hope for COVID ‘long-haulers’

Leronlimab’s Mechanism of Action in COVID-19 Published

Leronlimab role in COVID-19

Experimental Drugs Aim to Treat Long-Haul Covid Patients

Leronlimab and Long-Haulers

Research on Critically Ill COVID-19 Patients Published in Journal of Translational Autoimmunity

Case Study of Critically Ill Person with COVID-19 on ECMO Successfully Treated with Leronlimab Published in Journal of Translational Autoimmunity

Dr. Seethamraju’s Presentation at Special isirv-AVG Virtual Conference

Press Releases

Newsroom

Newsroom

  • Press Releases
  • Presentations

CytoDyn’s COVID-19 Long-Hauler’s Trial Closed as Enrollment Exceeds Goals

Apr 08, 2021 5:41pm EDT

CytoDyn Providing Leronlimab to a Philippine Hospital for 28 More COVID-19 Patients under Compassionate Special Permit (CSP)

Apr 07, 2021 4:01pm EDT

CytoDyn Signs Exclusive Supply and Distribution Agreement with Biomm S.A. in Brazil for COVID-19 and All Other Leronlimab Indications

Apr 07, 2021 6:00am EDT

CytoDyn Reschedules Webcast from April 6 to April 7

Apr 05, 2021 4:29pm EDT

CytoDyn Completes $28.5 Million Convertible Note Financing with Conversion Rate at $10.00 Per Share Without Warrants to Accelerate Manufacturing of Leronlimab Inventory

Apr 05, 2021 6:05am EDT

First Compassionate Special Permit (CSP) Patient in Philippines Improved Significantly 35 hours After First Injection of Leronlimab and Released 3 Days Later

Apr 05, 2021 6:00am EDT

CytoDyn to Hold Webcast on April 6 to Provide a Full Update on Its Activities

Apr 01, 2021 6:15am EDT

CytoDyn Files New Protocol with U.S. FDA for 4 Doses of Leronlimab for Critically Ill COVID-19 Patients with the Objective to Duplicate or Surpass 82% Survival Benefit with P-Value of 0.0233 Originally Achieved from Two Weeks of Treatment in CD12 Trial With 2 Doses

Apr 01, 2021 6:00am EDT

CytoDyn’s Leronlimab Decreased Mortality at 14 Days by 82% With Statistically Significant P-Value of 0.0233 Amongst Critically Ill COVID-19 Patients

Mar 30, 2021 6:00am EDT

Remarkable Turnaround Following Leronlimab Treatment in Critically Ill COVID-19 Patient After 84 days on ECMO; Case Study Published in Journal of Translational Autoimmunity

Mar 29, 2021 6:15am EDT
RSS
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...35
Next
© 2021 CytoDyn Inc. All Rights Reserved.
  • Twitter
  • Facebookj
Privacy Policy Disclaimer Sitemap